TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07881224: A Phase 1, Non-randomized, Fixed-sequence, Multiple-dose Study Investigating the Drug-drug Interaction Potential and QTc Effects of Fosmanogepix in Healthy Adult Subjects

Sponsor: Basilea Pharmaceutica · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 42 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07881224 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07881224 Rescue Dossier →